SMN1 copy number as a modifying factor of survival in Serbian patients with sporadic amyotrophic lateral sclerosis by Brkušanin, Milos et al.
 646
 
DOI: https://doi.org/10.2298/SARH180801069B
UDC: 616.833:575.1(497.11)
ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД 
 copy number as a modifying factor of survival 
in Serbian patients with sporadic amyotrophic 
lateral sclerosis
Miloš Brkušanin1, Irena Jeftović-Velkova2, Vladimir M. Jovanović3, Stojan Perić2, Jovan Pešović1, 
Goran Brajušković1, Zorica Stević2, Dušanka Savić-Pavićević1
1University of Belgrade, Faculty of Biology, Center for Human Molecular Genetics, Belgrade, Serbia;
2University of Belgrade, Faculty of Medicine, Clinical Center of Serbia, Neurology Clinic, Belgrade, Serbia;
3University of Belgrade, Siniša Stanković Institute for Biological Research, Department of Genetic 
Research, Belgrade, Serbia
SUMMARY
Introduction/Objective Amyotrophic lateral sclerosis (ALS) is a devastating motor neuron disease. The 
majority of cases are apparently sporadic ALS (SALS) with variants in susceptibility genes or sometimes 
in high-risk ALS genes. Two ALS susceptibility genes are SMN1, whose functional loss causes spinal mus-
cular atrophy (SMA), and a nearly identical SMN2 gene, which modulates SMA severity. In this study we 
examined the association of copy number variations (CNVs) of SMN1 and SMN2 genes and two additional 
genes, SERF1 and NAIP, residing in the same genomic region (i.e. 5q13.2 segmental duplication), with 
SALS in patients from Serbia. 
Methods Multiplex ligation-dependent probe amplification was used to determine CNVs of each gene 
in a clinically well-characterised group of 153 Serbian SALS patients and 153 controls.
Results Individual association between SMN1, SMN2, SERF1 or NAIP CNVs and SALS susceptibility or 
survival was not found. Survival curves based on the multivariable Cox regression analysis showed that 
three SMN1 copies, lower ALS Functional Rating Scale Revised (ALSFRS-R) score at the time of diagnosis, 
faster decline of the ALSFRS-R score over time, and shorter diagnostic delay result in shorter survival of 
Serbian SALS patients. 
Conclusion Clinical variables might be complemented with the SMN1 copy number to improve predic-
tion of survival in Serbian SALS patients.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an in-
curable and the most common late-onset mo-
tor neuron disease (MND) with an inexorably 
progressive course and mean survival around 
three to five years [1]. The incidence of ALS in 
Belgrade, Serbia, is 1.11/100,000 and worldwide 
crude incidence is 1.68/100,000 [2, 3]. Up to 
10% of ALS cases are familial, caused by mu-
tations in a growing number of genes [4]. The 
remaining ALS cases are considered sporadic 
(SALS), with no apparent family history of the 
disease. SALS is a multifactorial disease with 
multiple genetic factors of small effect size un-
derlying its pathogenesis. In addition, environ-
mental and stochastic factors and their interac-
tions act as precipitating factors in genetically 
susceptible individuals [4]. Furthermore, up 
to 10% of SALS patients carry variants in ALS 
genes associated with the familial form (high-
risk ALS genes) [5].
Candidate-gene and genome-wide associa-
tion studies identified numerous single nucle-
otide variants, but with an unclear contribu-
tion to disease pathogenesis [4, 6]. Addition-
ally, copy number variations (CNVs) represent 
important risk factors for a number of complex 
human disorders, including ALS [7]. Among 
them, 5q13.2 segmental duplication, harbor-
ing the survival of motor neuron (SMN) genes, 
was repeatedly studied due to its association 
with spinal muscular atrophy (SMA), the most 
common childhood-onset MND, and the in-
volvement of SMN and some ALS-associated 
proteins in common molecular pathways [8].
Functional loss of the SMN1 gene in the 
telomeric part of the 5q13.2 duplication causes 
SMA, while a nearly identical gene, called 
SMN2, located in its centromeric part, repre-
sents the major genetic modifier of the SMA 
phenotype. Case-control studies of SMN CNVs 
as risk factors for SALS susceptibility and sur-
vival have delivered varying results [9–12]. 
Meta-analyses provided firm evidence that the 
SMN1 duplication (three copies) can be con-
sidered a risk factor for SALS susceptibility [13, 
14]. Nevertheless, the mechanism behind the 
effect of SMN1 duplications on disease suscep-
tibility remains elusive. One of the assumptions 
is that SMN1 duplication might be accompanied 
by duplications of surrounding genes, whose 
structural rearrangements and/or impaired 
functions of their protein products could confer 
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the risk for SALS independent of the SMN protein [13]. 
However, an association of CNVs of SMN-flanking genes in 
the 5q13.2 duplication with SALS has not been investigated. 
The closest gene to SMN is the SERF1 (small EDRK-rich 
factor 1, previous gene symbol H4F5) gene, which exists 
in two identical copies – SERF1A (telomeric) and SERF1B 
(centromeric). The SERF1 protein is a general regulator of 
protein aggregation and proteotoxicity. The NAIP (NLR 
family apoptosis inhibitory protein) gene exists as a full-
length telomeric copy and additional pseudogene copies. 
The NAIP protein acts as a neuroprotector by the inhibition 
of motor neuron apoptosis. Deletions of telomeric copies 
of NAIP and particularly SERF1 mostly accompany dele-
tions of the neighboring SMN1 gene in SMA patients [15]. 
However, duplications of NAIP were detected in ~7.5% of 
chromosomes carrying one SMN1 copy [15].
The aim of this study was to investigate whether the 
SMN1, SMN2, SERF1, and NAIP CNVs confer the risk 
for SALS. We also examined their modulatory effect on 
survival in a clinically well-characterized group of SALS 
patients from Serbia, either as independent variables, or 
as variables that could complement clinical variables in 
disease prognosis.
METHODS
Subjects
A total of 154 SALS patients (91 males and 63 females), 
who met the revised El Escorial criteria for probable or 
definite ALS and had no apparent family history of the 
disease [16], were recruited from January 2015 until June 
2017 at the Neurology Clinic, Clinical Center of Serbia, 
Belgrade, Serbia. One patient was excluded from the study 
due to neoplasm of the spinal cord since this affected his 
functionality and course of the disease. All the remaining 
153 patients (90 males and 63 females) were screened for 
two major causative mutations in Serbian ALS patients [17] 
in two high-risk ALS genes – p.Leu145Phe (c.435G>C, En-
sembl transcript SOD1-201 ENST00000270142.10) muta-
tion in the SOD1 gene and the expansion of the GGGGCC 
repeat in the C9orf72 gene (mutation = [GGGGCC] > 30). 
Demographic and clinical characteristics of patients are 
shown in Table 1. A total of 153 (90 males and 63 females) 
unrelated age-matched individuals from the general Ser-
bian population were used as controls. The study was ap-
proved by the Ethics Committee of the Clinical Center 
of Serbia (number 339/4) in concordance with principles 
of the Declaration of Helsinki and informed consent was 
obtained from all participants.
Genetic analyses
Genomic DNA was extracted from blood samples using 
the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, 
Germany) and quantified with the Qubit dsDNA BR 
Assay Kit (Thermo Fisher Scientific, Grand Island, NY, 
USA). Screening of the SOD1 p.Leu145Phe mutation was 
performed by PCR and CviKI-1 digestion (New Eng-
land Biolabs, Ipswich, MA, USA), while screening of the 
C9orf72 expansion was done by conventional and repeat 
primed PCR [18]. Multiplex ligation-dependent probe am-
plification (MLPA), using the P021 A2 probe mix (MRC-
Holland, Amsterdam, the Netherlands), was performed 
according to the manufacturer’s guidelines to determine 
CNVs of the SMN1, SMN2, SERF1, and NAIP genes. Ap-
proximately 200 ng of DNA was used for each reaction. 
Since MLPA is a relative quantification technique, all sam-
ples were compared with 15 reference samples using the 
Coffalyser.Net software (MRC-Holland, Amsterdam, the 
Netherlands). Ratios of MLPA probes specific for 5q13.2 
genes and the assigned copy numbers were as previously 
described [15]. Reproducibility of the MLPA method was 
determined by running ~30% of randomly selected sam-
ples in independent duplicates and by obtaining identi-
cal results between the replicas. All samples were blindly 
analyzed regardless of clinical data.
Statistical analyses
All statistical analyses were carried out in the R ver. 3.3.3 
with the significance level set at 0.05 [19]. In case of mul-
tiple comparisons, the Bonferroni correction was used to 
Table 1. Demographic and clinical characteristics of 153 examined 
Serbian SALS patients. Longitudinal ΔALSFRS and ΔFVC scores were 
available for 91 and 71 patients, respectively.
Demographic and clinical variables Values
Sex, n (%)
Female 63 (41.2)
Male 90 (58.8)
Age at onset, mean ± SD, years 58.9 ± 10.3
Diagnostic delay, mean ± SD, months 14.1 ± 11.4
Symptoms at onset, n
Bulbar 25
Spinal 126
NA 2
Site of onset for spinal-onset cases, n
Arms 54
Legs 62
Arms and legs 10
Motor neuron affected, n
Upper 17
Lower 31
Upper and lower 100
NA 5
ALSFRS-R scoret1, median (range) 39 (6–48)
ΔALSFRS*, median (range) 0.94 (0–5.54)
FVCt1, median (range) 90 (29–157)
ΔFVC*, median (range) 1.94 (0–30)
MMSE score, median (range) 28 (16–30)
Riluzole, n 35
Dead in June 2017, n 54
n – number of patients; NA – not available; ALSFRS-Rt1 – Revised ALS 
Functional Rating Scale score at the time of diagnosis (t1); FVCt1 – forced vital 
capacity at the time of diagnosis (t1); Δ – change over time; MMSE – Mini Mental 
State Examination score at the time of collection of blood samples (t2);
*change in the ALSFRS-R score and FVC over time was calculated as follows:
ΔALSFRS = (ALSFRS-Rt2 - ALSFRS-Rt1) / t2 - t1 and ΔFVC = (FVCt2 - FVCt1) / t2 - t1
SMN1 CNVs modulate survival of patients with sporadic ALS
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correct the significance level. The association of the SMN1, 
SMN2, SERF1, and NAIP gene copy numbers with SALS 
was tested by Fisher’s exact test.
Survival of patients was analyzed and visualized using 
the survival and survminer R packages. Cumulative sur-
vival probability was estimated using the Kaplan–Meier 
method. Survival curves of subgroups of patients (strata) 
within each genetic, demographic, and clinical variable 
were compared by the log-rank test and continuous vari-
ables were dichotomized with a cut-off to form strata. Age 
at onset, ALS Functional Rating Scale Revised (ALSFRS-R) 
at the time of diagnosis and diagnostic delay were dichoto-
mized using the median split, whereas the cut-off value 
for Mini Mental State Examination (MMSE) and forced 
vital capacity (FVC), both at the time of diagnosis, was the 
one below which findings are indicative of mild cognitive 
impairment (< 24) or respiratory compromise (< 90%), 
respectively [20].
Assuming that effect of a single contributing factor may 
be of small size and obscured or confounded by other fac-
tors, the effect of multiple factors on survival was tested by 
the multivariable Cox regression analysis. The univariable 
Cox regression analysis was performed as a screening tool 
for the selection of clinical variables (covariates) for the 
multivariable Cox regression analysis. The overall signifi-
cance of the Cox model was described by the likelihood 
ratio test (LRT) for the global null hypothesis. Percentage 
of the variance in survival in both Cox regression analyses 
was estimated by the R2 value. To verify the proportional 
hazards assumption, for each covariate in the obtained Cox 
model and for the model as a whole, the corresponding set 
of scaled Schoenfeld residuals was correlated with time to 
test for their independence. The proportional hazards as-
sumption is violated if a statistically significant relationship 
between residuals and time is found.
RESULTS
In a total of 153 Serbian SALS patients, we identified 10 
patients (6.54%) with the SOD1 p.Leu145Phe mutation and 
nine patients (5.88%) with the expansion of the GGGGCC 
repeat in the C9orf72 gene.
No statistically significant association was found be-
tween CNVs of SMN1 (p = 0.650, Fisher’s exact test), 
SMN2 (p = 0.369), SERF1 (p = 0.257) or NAIP (p = 0.908) 
genes and SALS susceptibility in the examined group of 
Serbian patients (Table 2).
Median survival time was 22 months (Figure 1). The 
univariable Cox regression analysis revealed that the over-
all survival was statistically significantly influenced by 
the following protective factors: ALSFRS-R score (hazard 
ratio [HR] = 0.939, 95% CI 0.910–0.968, p = 1.415e-04) 
and FVC (HR = 0.975, 95% CI 0.964–0.987, p = 8.799e-
05), both at the time of diagnosis, and diagnostic delay 
(HR = 0.955, 95% CI 0.921–0.990, p = 3.025e-03); and by 
the following risk factor: change of the ALSFRS-R score 
over time (ΔALSFRS: HR = 2.253, 95% CI 1.713–2.964, 
p = 4.886e-07) (Table 3). For the SMN1 copy number we 
observed a statistical trend (HR = 1.811, 95% CI 0.910–
3.607, p = 0.091). However, ΔALSFRS showed the strongest 
effect explaining 24.3% of the survival variance.
In order to estimate the direction of each variable’s ef-
fect, the univariable Cox regression analysis was repeated 
by converting continuous data into categorical using the 
median split. The following protective strata were identi-
fied: ALSFRS-R score > 39 (HR = 0.299, 95% CI 0.161–
0.555), FVC > 90% (HR = 0.249, 95% CI 0.138–0.450), 
diagnostic delay > 11 months (HR = 0.541, 95% CI 0.311–
0.942), as well as the following risk stratum: ΔALSFRS 
> 0.9 (HR = 8.249, 95% CI 3.08–22.1).
Log-rank test showed that survival was significantly 
shorter in subgroups of older age (> 60 years, p = 1.7e-
02), lower ALSFRS-R (≤ 39, p = 5e-05) and lower FVC 
Table 2. Distribution of the SMN1, SMN2, SERF1, and NAIP gene copy 
numbers in Serbian SALS patients (n = 153) and controls (n = 153)
Gene Copy number Patients Controls p-value*
SMN1
1 6 9
0.6502 134 134
3 13 10
SMN2
0 6 10
0.369
1 62 54
2 82 82
3 3 7
SERF1
2 3 3
0.257
3 18 30
4 127 114
5 5 6
NAIP
1 11 12
0.908
2 119 115
3 20 20
4 3 5
5 0 1
*Fisher’s exact test
Figure 1. The Kaplan–Meier curve of cumulative survival probability 
from the time of diagnosis for examined Serbian SALS patients (n = 153)
× – censored patients; shaded area – 95% confidence interval
Brkušanin M. et al.
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(≤ 90%, p = 7.1e-07) at the time of diagnosis, lower MMSE 
score (< 24, p = 4.3e-04), shorter diagnostic delay (< 11 
months, p = 2.7e-02) and in a group with both upper and 
lower motor neurons affected (p = 2.6e-02). Even though 
differences in the survival of patients with different SMN1 
copy number were not statistically significant (p = 0.242), 
their median survival times were different: those with one 
SMN1 copy did not reach the estimated median survival 
time of 50%, those with two SMN1 copies had median sur-
vival time of 22 months, while patients with three SMN1 
copies had median survival time of 19 months.
The multivariable Cox regression analysis included 
only statistically significant variables from the univariable 
Cox analysis (ALSFRS-R, FVC, ΔALSFRS, and diagnos-
tic delay), with the addition of examined genetic factors 
(SMN1, SMN2, SERF1, and NAIP copy number). For a 
total of 90 SALS patients, out of whom 28 died, the values 
of all variables included in the model were available. The 
multivariable Cox regression analysis explained 41.2% 
of the survival variance in SALS patients and identified 
ALSFRS-R score at the time of diagnosis (HR = 0.885, 
95% CI 0.834–0.938), change of the ALSFRS-R score over 
time (HR = 2.193, 95% CI 1.618–2.972), diagnostic delay 
(HR = 0.939, 95% CI 0.888–0.994) and SMN1 copy number 
(HR = 10.276, 95% CI 3.106–33.998) as significant inde-
pendent predictors of survival (Table 4). Lower ALSFRS-R 
score at the time of diagnosis, faster decline of the overall 
functionality (ΔALSFRS), shorter diagnostic delay and 
higher number of SMN1 copies resulted in shorter sur-
vival of Serbian SALS patients. Patients with one SMN1 
copy had survival probability of 100%, patients with two 
SMN1 copies had survival probability of 39.2%, while those 
with three SMN1 copies had the lowest survival probabil-
ity of only 0.03% (Figure 2). The assumption of propor-
tional hazards was not violated (for ALSFRS p = 0.325; 
for ΔALSFRS p = 0.088; for diagnostic delay p = 0.548; 
for SMN1 copy number p = 0.265; for the whole model 
p = 0.329), confirming the validity of the model.
DISCUSSION
About 1 2% of SALS patients had either SOD1 p.Leu145Phe 
or C9orf72 repeat expansion. High frequency of 
p.Leu145Phe mutation in our study and other cohorts from 
Southern Europe suggests a probable founder effect [17, 
21]. On the other hand, the frequency of the C9orf72 repeat 
expansions in the Serbian SALS patients was in agreement 
with literature data [22]. Among 19 SALS patients with 
the SOD1 p.Leu145Phe mutation or the C9orf72 repeat 
expansion, three SMN1 copies were present in two SOD1-
positive patients. Co-occurrence of a high-risk variant 
Table 3. Results of the univariable Cox proportional hazards analysis of censored survival data for examined Serbian SALS patients
Predictor variable HR HR 95% CI R2 LRT LRT p-value n d
SMN1 1.811 0.910–3.607 0.017 2.68 9.1e-02 153 54
Age at onset 1.029 1.001–1.058 0.028 4.32 3.761e-02 151 53
Diagnostic delay 0.955 0.921–0.990 0.056 8.6 3.025e-03 149 52
ALSFRS-R 0.939 0.910–0.968 0.093 14.48 1.415e-04 149 53
ΔALSFRS 2.253 1.713–2.964 0.243 25.31 4.886e-07 91 28
FVC 0.975 0.964–0.987 0.109 15.38 8.799e-05 133 46
HR – hazard ratio; R2 – coeffi  cient of determination; LRT – likelihood ratio test; n – number of patients; d – number of dead patients; ALSFRS-R – Revised ALS 
Functional Rating Scale; FVC – forced vital capacity; Δ – change over time; p-values of statistically signifi cant variables are presented and those signifi cant after 
the Bonferroni’s correction for 16 clinical variables are given in bold (5.0e-02/16 = 3.1e-03)
Table 4. The multivariable Cox model with statistically significant variables for survival in Serbian SALS patients (n = 90)
Predictor variable HR HR 95% CI R2 of the model LRT LRT p-value n d
ALSFRS 0.885 0.834–0.938
0.412 47.83 1.022e-09 90 28
ΔALSFRS 2.193 1.618–2.972
Diagnostic delay 0.939 0.888–0.994
SMN1 copy number 10.276 3.106–33.998
HR – hazard ratio; R2 – coeffi  cient of determination; LRT – likelihood ratio test; n – number of patients; d – number of dead patients; ALSFRS-R – Revised ALS 
Functional Rating Scale; Δ – change over time
Figure 2. Survival curves of the influence of SMN1 copy number based 
on the Cox model that included SMN1 copy number, ALSFRS-R score 
at the time of diagnosis, change of the ALSFRS-R score over time and 
diagnostic delay (n = 90)
Dotted line – one SMN1 copy; shaded line – two SMN1 copies; solid line – three 
SMN1 copies
SMN1 CNVs modulate survival of patients with sporadic ALS
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with susceptibility variants has been reported in a small 
percent of patients from a large ALS cohort [22].
To our knowledge, this is the first study examining 
CNVs of genes in 5q13.2 duplication other than SMN as 
risk factors for SALS susceptibility and survival. Former 
studies took the NAIP gene into consideration; nonethe-
less, due to methodological limitations, they could only 
detect its homozygous deletion [23]. Despite the absence of 
association in our study, a recent study by Kano et al. [24] 
reported that the NAIP protein level in ALS patients was 
lower by nearly half compared to healthy controls. These 
latest findings and the implication of SERF1 CNVs in the 
SMA clinical outcome justify research efforts focused on 
the role of NAIP and SERF1 CNVs in SALS [15].
Lack of association between SMN1 and SMN2 copy 
numbers and SALS in Serbian patients compared to previ-
ous results might be, at least partially, explained by а differ-
ent genetic architecture of diverse populations [12]. Meta-
analyses have supported SMN1 duplication as a major risk 
factor for SALS susceptibility, but the analyzed samples 
mostly included patients from Western Europe [13, 14]. 
Additionally, in a recent paper, the SMN1 gene has been 
investigated as an ALS susceptibility gene with intermedi-
ate effect and its duplication was found in a larger number 
of sporadic cases (6.6%) compared to controls (3.4%) [22]. 
It is of note that the frequency of heterozygous deletion 
of SMN1 in our control group is twice as high as what is 
expected according to the literature (9/153 in our study, 
compared to 1/35) [25]. To our knowledge, this is the first 
study showing a higher frequency of one SMN1 copy in 
the controls than in SALS patients, which might explain 
the absence of association between one SMN1 copy and 
SALS susceptibility.
Clinical factors with the highest predictive strength 
on ALS survival are respiratory status and the ALSFRS-R 
score, particularly their change over time [26, 27]. How-
ever, prognosis based on these two clinical variables alone 
may be uncertain for clinical use given that motor neuron 
death may occur prior to the appearance of symptoms. 
Complementing clinical variables with objectively measur-
able time-invariant genetic factors may help develop better 
clinically useful algorithms.
Our results show that SMN1 copy number, together 
with the ALSFRS-R score at the time of diagnosis, its 
change over time, and diagnostic delay might be useful to 
predict survival in Serbian SALS patients. Survival curves 
demonstrate that three SMN1 copies result in a higher 
mortality rate compared to one copy. Previous studies also 
showed that SMN CNVs might influence the survival of 
SALS patients. Lower SMN1 copy number has been associ-
ated with an increased mortality rate in Dutch and French 
patients [10, 11]. The absence or decrease of SMN2 copy 
number has been identified as a negative prognostic factor 
for survival in Dutch patients [10, 28], while homozygous 
absence of SMN2 has been observed as a protective factor 
in Swedish patients [12]. These data additionally underline 
the significance of performing gene association studies in 
diverse populations. Although the mechanism by which 
the increased SMN1 copy number could contribute to 
shorter survival in ALS patients remains unknown, the 
study on zebrafish showed that the highest temporal re-
quirement for SMN is in the earliest stages of development, 
while the study on mice showed that only moderate SMN 
levels are required in the adult central nervous system 
compared to neonatal mice [29, 30].
Our analysis revealed that the lower ALSFRS-R score at 
the time of diagnosis, faster change in the ALSFRS-R score 
over time, and shorter diagnostic delay result in higher 
mortality percentage, reflecting a greater overall functional 
impairment during the natural course of the disease. Ad-
ditionally, our results support a better prognostic value of 
longitudinal than cross-sectional data for ALSFRS-R score 
regarding survival of SALS patients, given that the R2 value 
of ΔALSFRS-R was twice as high as it was for ALSFRS-R 
at the time of diagnosis [26].
The limitation of our study is its relatively small sam-
ple size, which is a common occurrence in rare disease 
population studies, and the recruitment of a significantly 
larger SALS sample is hampered by the small size of the 
population of Serbia. Therefore, the solidity of our findings 
should be verified on a larger study sample from different 
ethnic origins, and meta-analyses. However, the present 
study puts an emphasis on a clinically well-characterized 
sample and on collecting follow-up data. It also offers in-
sight into genetic architecture of the 5q13.2 duplication 
in SALS patients from a Southeast European population. 
Compared to qPCR mostly used in previous studies, MLPA 
utilizes one primer pair to amplify multiple genes of inter-
est eliminating the error that might arise due to differences 
in PCR efficiency of target and normalization primers.
CONCLUSION
Our finding regarding the modulating role of SMN1 CNVs 
on the survival of Serbian SALS patients might lead to a 
modeling of a stronger, more reliable and practical prog-
nostic algorithm in SALS, in which clinical predictive fac-
tors are complemented with more objective, time-invariant 
genetic factors. This may, in turn, enable more precise 
prognosis and more targeted clinical trials.
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САЖЕТАК 
Увод/Циљ Амиотрофична латерална склероза (АЛС) пред-
ставља тешко обољење моторног неурона. Већина случајева 
је наизглед спорадична, са варијантама у високоризичним 
АЛС генима или генима асоцираним са АЛС. Два гена асоци-
рана са АЛС су SMN1, чије функционално одсуство узрокује 
спиналну мишићну атрофију (СМА), и њему готово иденти-
чан ген SMN2, који је модификатор фенотипа СМА. Оба гена 
смештена су у сегменталној дупликацији 5q13.2.
Циљ студије био је испитивање асоцијације броја копија 
гена SMN1 и SMN2, као и гена SERF1 и NAIP, смештених у 
истом геномском региону, са ризиком за развој болести и 
преживљавање код болесника из Србије са спорадичном 
формом АЛС (САЛС).
Методе Мултипла лигационо-зависна амплификација је 
коришћена за одређивање броја копија гена SMN1, SMN2, 
SERF1 и NAIP у клинички детаљно окарактерисаној групи од 
153 болесника са САЛС из Србије и 153 контролне особе.
Резултати Асоцијација броја копија гена SMN1, SMN2, SERF1 
или NAIP са ризиком за развој САЛС или преживљавањем 
није показана. Криве преживљавања засноване на мулти-
варијабилној Коксовој регресионој анализи показале су 
да три копије SMN1, нижи збир скале ALSFRS-R у тренутку 
дијагнозе, бржи пад збира ALSFRS-R током времена и краће 
дијагностичко кашњење резултују краћим преживљавањем 
болесника са САЛС из Србије.
Закључак Прогноза преживљавања болесника са САЛС за-
снована на клиничким параметрима може бити унапређена 
коришћењем генетичког параметра – броја копија SMN1.
Кључне речи: преживљавање моторног неурона; амиотро-
фична латерална склероза; H4F5; NAIP; SMN1
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